Jazz Pharmaceuticals plc (FRA:J7Z)

Market Cap	8.41B +16.2%
Revenue (ttm)	3.54B +4.1%
Net Income	-314.06M
EPS	-5.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	7.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	134.85
Previous Close	136.60
Day's Range	134.85 - 138.50
52-Week Range	86.20 - 158.25
Beta	n/a
RSI	44.66
Earnings Date	Feb 26, 2026

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enry...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 2,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: J7Z

Financial Performance

In 2024, Jazz Pharmaceuticals's revenue was $4.07 billion, an increase of 6.12% compared to the previous year's $3.83 billion. Earnings were $560.12 million, an increase of 35.02%.

Financial numbers in USD